Claims
- 1. A method of reducing human serum levels of HBV DNA and HBV DNA polymerase which comprises administering to such human a therapeutic amount of a composition comprising a compound of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuroanosyl)-5-iodouracil (FIAU), the prodrug 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC) or the metabolite 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)uracil (FAU) and a pharmaceutically acceptable carrier.
- 2. The method of claim 1 in which said composition is administered orally.
- 3. The method of claim 1 in which said composition is administered parenterally.
- 4. The method of claim 1 in which said treatment includes one or more administrations of said composition per day for a treatment period of about 7 to about 28 consecutive days.
- 5. The method of claim 4 in which said treatment period is about 14 consecutive days.
- 6. The method of claim 1 wherein the therapeutic amount of said composition ranges between about 0.05 to about 1 mg/kg-day.
- 7. The method of claim 1 wherein said composition contains an amount of said compound selected from the group consisting of about 0.25, 0.5, 1, 2 and 5 mg.
- 8. A method of reducing serum levels of HBV DNA and HBV DNA polymerase in human patients by administering to said patients a pharmaceutical composition comprising an amount of a compound of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU), the prodrug 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC) or the metabolite 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)uracil (FAU) and a pharmaceutically acceptable carrier sufficient to provide a dosage of said compound in the range of about 0.05 to 1 mg/kg-day, and a pharmaceutically acceptable carrier.
- 9. A method for reducing serum levels of HBV DNA and HBV DNA polymerase in human patients by administering to said patients a pharmaceutical composition comprising an amount of the compound FIAU, the prodrug 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodocytosine (FIAC) or the metabolite 1-(2'-deoxy-2'fluoro-.beta.-D-arabinofuranosyl)uracil (FAU) and a pharmaceutically acceptable carrier sufficient to provide said patients with a steady state peak plasma concentration of said compound in the range of about 0.1 to about 1 .mu.g/ml.
- 10. The method of claim 8 or 9 wherein said composition is administered orally.
- 11. The method of claim 8 or 9 wherein said composition is administered parenterally.
- 12. The method of claim 8 or 9 in which said treatment includes one or more administrations of said composition per day for a treatment period of about 7 to about 28 consecutive days.
- 13. The method of claim 12 in which said treatment period is about 14 consecutive days.
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of prior, U.S. application Ser. No. 07/952,927, filed Sep. 25, 1992, now abandoned, which in turn, is a continuation in part of prior, U.S. application Ser. No. 07/863,890, filed Apr. 6, 1992, now abandoned, the complete disclosures of which are incorporated by reference herein.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4211773 |
Lopez et al. |
Jul 1980 |
|
4594339 |
Lopez et al. |
Jun 1986 |
|
4666892 |
Fox et al. |
May 1987 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0147774 |
Feb 1976 |
DEX |
Non-Patent Literature Citations (2)
Entry |
Fried, M. W. et al.; Hematology, vol. 16, No. 4 Pt. 2 (1992), p. 127 A. |
Hantz, O. et al.; Antiviral Research, vol. 4, No. 4 (1984), pp. 187-199. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
952927 |
Sep 1992 |
|
Parent |
863890 |
Apr 1992 |
|